New-Gen EVAR Tech Should Allay Concerns Over Not-So-Favorable New Data
This article was originally published in Clinica
Executive Summary
New data on the long-term clinical benefits of endovascular aortic repair (EVAR) have put the minimally invasive technique in a less than favorable light. However, these findings are not expected to dent the market for these devices as continued improvements in newer-generation EVAR systems, such as Medtronic’s Endurant, appear successful in countering the technology’s known shortcomings.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.